Status:
UNKNOWN
Convalescent Plasma Therapy in Severe COVID-19 Infection
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Collaborating Sponsors:
Dhaka Medical College
Conditions:
Covid19
Convalescence
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
As of March 18, 2020, COVID-19 cases were reported in approximately 195 countries. No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, such as remdesivir and favi...
Detailed Description
Rationale of the Study Currently no specific treatment is available against COVID-19 infection. Supportive treatment along with concentrated oxygen is the only mean of treatment. Researchers have alre...
Eligibility Criteria
Inclusion
- Respiratory rate \> 30 breaths/min; PLUS
- Severe respiratory distress; or SpO2 ≤ 88% on room air or PaO2/FiO2≤ 300 mm of Hg, PLUS
- Radiological evidence of bilateral lung infiltrate, AND OR
- Systolic BP \< 90 mm of Hg or diastolic BP \<60 mm of Hg. AND OR
- Criteria 1 to 4 AND or patient in Ventilator support
Exclusion
- Patients below18 years.
- Pregnant women and breast-feeding mothers.
- Previous history of allergic reaction to plasma
- Those who will not give consent
Key Trial Info
Start Date :
May 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04403477
Start Date
May 20 2020
End Date
October 30 2020
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1200